Search

Context.--Identification of the site of origin of carcinoma of unknown primary using immunohistochemistry is a frequent requirement of anatomic pathologists. Diagnostic accuracy is crucial, particularly in the current era of targeted therapies and smaller sample sizes. Objectives.--To provide practical guidance and suggestions for classifying carcinoma of unknown primary using both proven and new antibodies, as well as targeting panels based on integration of morphologic and clinical features. Data Sources.--Literature review, the authors' practice experience, and authors' research. Conclusions.--With well-performed and interpreted immunohistochemistry panels, anatomic pathologists can successfully identify the site of origin of carcinoma of unknown primary. It is crucial to understand not only the diagnostic uses of the many available antibodies but also the potential limits and pitfalls. [ABSTRACT FROM AUTHOR]

The article deals with human epidermal growth factor receptor 2 (HER2) immunohistochemical and fluorescence in situ hybridization (FISH) testing in breast cancer. A guideline has been created in 2007 by the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) to address the knowns and the unknowns of this testing. A study by E. Manion et al was also published in June 2011 which focused on the impact of the choice of antibody clone used for HER2 testing.